Financhill
Back

Crinetics Pharmaceuticals, Inc. Vs. Nebius Group NV Industry Stock Comparison

Sell
27

CRNX
Crinetics Pharmaceuticals, Inc.

Last Price:
$37.24
Seasonality Move:
6.81%
Buy
51

NBIS
Nebius Group NV

Last Price:
$108.86
Seasonality Move:
16.36%
Sell
27
Crinetics Pharmaceuticals, Inc. (CRNX) is a Sell

Is Crinetics Pharmaceuticals, Inc. a Buy, Sell or Hold?

  • The current Crinetics Pharmaceuticals, Inc. [CRNX] share price is $37.23. The Score for CRNX is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.
  • CRNX is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Buy
51
Nebius Group NV (NBIS) is a Buy

Is Nebius Group NV a Buy, Sell or Hold?

  • The current Nebius Group NV [NBIS] share price is $108.82. The Score for NBIS is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.
  • NBIS is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.

CRNX Stock Price Chart

What is Crinetics Pharmaceuticals, Inc.'s stock price today?

  • The Crinetics Pharmaceuticals, Inc. share price today is $37.23
    The current trend is relatively stagnant and CRNX is experiencing buying pressure, which is a positive indicator for future bullish movement.

NBIS Stock Price Chart

What is Nebius Group NV's stock price today?

  • The Nebius Group NV share price today is $108.82
    Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and NBIS is experiencing buying pressure, which is a positive indicator for future bullish movement.

CRNX Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -1.67 Sell
Relative Strength Index (14 RSI): 46.65 Sell
Chaikin Money Flow: 1144076 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (35.19 - 39.01) Buy
Bollinger Bands (100): (39.09 - 50.79) Sell

NBIS Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): 1 Buy
Relative Strength Index (14 RSI): 52.24 Buy
Chaikin Money Flow: 13258215 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (94.12 - 116.9) Buy
Bollinger Bands (100): (86.58 - 107.22) Buy

CRNX Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 35.64 Buy
20-day SMA: 36.36 Buy
50-day SMA: 42.18 Sell
200-day SMA: 39.83 Sell
8-day EMA: 36.06 Buy
20-day EMA: 37.06 Buy
50-day EMA: 40.53 Sell
200-day EMA: 41.45 Sell

NBIS Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 105.45 Buy
20-day SMA: 108.76 Buy
50-day SMA: 99.99 Buy
200-day SMA: 89.14 Buy
8-day EMA: 105.76 Buy
20-day EMA: 106.36 Buy
50-day EMA: 102.68 Buy
200-day EMA: 86.85 Buy

Crinetics Pharmaceuticals, Inc. Earnings Growth & CRNX Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.13 per share, an increase next quarter of $0.14 per share, an increase this year of $0.24 per share, and an increase next year of $0.70 per share.

Nebius Group NV Earnings Growth & NBIS Earnings Dates

  • Analysts estimate an earnings decrease this quarter of $0.10 per share, an increase next quarter of $0.82 per share, a decrease this year of $0.72 per share, and an increase next year of $1.68 per share.

Crinetics Pharmaceuticals, Inc. Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Nebius Group NV Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):